Skip to main content
Fig. 4 | Respiratory Research

Fig. 4

From: Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator

Fig. 4

Mean change from baseline in FEV1 over 36 h (per protocol population). Data are LS means ± standard error. The number of patients exposed to each treatment differed from the number of non − missing observations for navafenterol 1800 μg (at 45 min and 2 h; both n = 30) and placebo (at 12 and 14 h; n = 31 and n = 30, respectively). FEV1 = forced expiratory volume in 1 s; LS = least squares

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us